--- title: "投資者警示：Robbins LLP 通知投資者關於 Corcept Therapeutics Inc. 的集體訴訟" description: "Robbins LLP 宣佈對在 2024 年 10 月 31 日至 2025 年 12 月 30 日期間購買 Corcept Therapeutics Inc.（納斯達克：CORT）股票的投資者提起集體訴訟。訴訟指控 Corcept 在其產品候選藥物 relacorilant 治療高皮質醇血癥的可行性方面誤導了投資者。美國食品藥品監督管理局（FDA）對支持 Corcept 新藥申請的臨牀證據表示" type: "news" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/276498684.md" published_at: "2026-02-21T01:24:48.000Z" --- # 投資者警示：Robbins LLP 通知投資者關於 Corcept Therapeutics Inc. 的集體訴訟 > Robbins LLP 宣佈對在 2024 年 10 月 31 日至 2025 年 12 月 30 日期間購買 Corcept Therapeutics Inc.（納斯達克：CORT）股票的投資者提起集體訴訟。訴訟指控 Corcept 在其產品候選藥物 relacorilant 治療高皮質醇血癥的可行性方面誤導了投資者。美國食品藥品監督管理局（FDA）對支持 Corcept 新藥申請的臨牀證據表示擔憂，導致在 FDA 於 2025 年 12 月 31 日發出完整回應函後，股價大幅下跌。股東可能有資格參與該集體訴訟 **Investor Alert: Robbins LLP Informs Investors of the Corcept Therapeutics Inc. Class Action Lawsuit** Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporation (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025. Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. **The Allegations:** Robbins LLP is Investigating Allegations that Corcept Therapeutics Incorporated (CORT) Misled Investors Regarding the Viability of its New Product Candidate According to the complaint, one of Corcept's lead new product candidates is relacorilant, which is being developed for multiple indications, including as a treatment for patients with hypercortisolism (also known as “Cushing’s syndrome”). During the class period, defendants represented that the key clinical trials supporting the use of relacorilant as treatment for patients with hypercortisolism were “powerful support” for the New Drug Application (“NDA”) that Corcept submitted to the U.S. Food and Drug Administration (“FDA”) for this indication. Defendants also stated that they had communicated with the FDA about this NDA and were confident in submitting the NDA, foreseeing no impediments to approval. Toward the latter part of the class period, Defendants repeatedly told investors that “relacorilant is approaching approval.” Plaintiff alleges that in truth, the FDA had raised concerns about the adequacy of the clinical evidence supporting the NDA and, as a result there was a known material risk that Corcept's relacorilant NDA would not be approved. The complaint continues that on December 31, 2025, Corcept revealed that the FDA had issued a Complete Response Letter (“CRL”) regarding the NDA for relacorilant as a treatment for patients with hypercortisolism. The press release issued by the Company stated that the FDA had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.” As a result of this disclosure, the price of Corcept common stock declined from a closing price of $70.20 on December 30, 2025, to a closing price of $34.80 on December 31, 2025, or 50.4%. **What Now**: You may be eligible to participate in the class action against Corcept Therapeutics Incorporated. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. ***All representation is on a contingency fee basis. Shareholders pay no fees or expenses.*** **About Robbins LLP****:** A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Corcept Therapeutics Incorporated settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. Aaron Dumas, Jr. Robbins LLP 5060 Shoreham Pl., Ste. 300 San Diego, CA 92122 adumas@robbinsllp.com (800) 350-6003 www.robbinsllp.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260220335365/en/ ### Related Stocks - [BBH.US - 生物科技 ETF - VanEck Vectors](https://longbridge.com/zh-HK/quote/BBH.US.md) - [IBB.US - 納斯達克生物科技指數 ETF - iShares Nasdaq](https://longbridge.com/zh-HK/quote/IBB.US.md) - [XLV.US - 醫療業 ETF - SPDR](https://longbridge.com/zh-HK/quote/XLV.US.md) - [IHE.US - 美國制藥 ETF - iShares](https://longbridge.com/zh-HK/quote/IHE.US.md) - [PBE.US - 動態生物技術與基因組 ETF - Invesco](https://longbridge.com/zh-HK/quote/PBE.US.md) - [FBT.US - 紐交所高增長板生物技術指數 ETF - First Trust](https://longbridge.com/zh-HK/quote/FBT.US.md) - [VHT.US - 醫療業 ETF - Vanguard](https://longbridge.com/zh-HK/quote/VHT.US.md) - [ARKG.US - 基因改革 ETF - ARK](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [SBIO.US - 醫藥突破 ETF - ALPS](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [CORT.US - Corcept醫療](https://longbridge.com/zh-HK/quote/CORT.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 阿伯丁集团有限公司持有 Crinetics Pharmaceuticals, Inc. $CRNX 价值 1416 万美元的股票 | 阿伯丁集团 plc 在第三季度将其在 Crinetics Pharmaceuticals, Inc. 的股份增加了 21.3%，目前持有 339,949 股，价值 1416 万美元。其他机构投资者也调整了他们的持股。分析师对 CRNX 的评 | [Link](https://longbridge.com/zh-HK/news/276426109.md) | | BUZZ-Traws Pharma 在 FDA 将流感药物申请置于临床搁置后股价下跌 | Traws Pharma 的股票在盘前交易中下跌了 20.81%，至 1.58 美元，此前美国 FDA 因对 tivoxavir marboxil 的突变性数据表示担忧，将其新药申请置于临床暂停状态。该公司表示，此次暂停不会影响美国以外的正 | [Link](https://longbridge.com/zh-HK/news/276337113.md) | | Madrigal 制药因 Rezdiffra 的销售，第四季度收入大幅增长 | Madrigal 制药报告第四季度收入为 3.211 亿美元，较去年大幅增长，尽管出现了净亏损。该公司预计，由于疾病意识的提高，Rezdiffra 的销售将实现强劲增长，并计划与 FDA 就第二阶段试验设计进行咨询。MASH 管道已通过新项 | [Link](https://longbridge.com/zh-HK/news/276330392.md) | | 关键事实：Candel Therapeutics 获得 1 亿美元资金；计划推出新药 | Candel Therapeutics 已与 RTW Investments 达成了一项 1 亿美元的融资协议，用于其治疗药物 Aglatimagene Besadenovec，待 FDA 批准，且根据美国销售情况支付版税。Candel T | [Link](https://longbridge.com/zh-HK/news/276481541.md) | | 艾伯维公司 SEC 10-K 年度报告 | 艾伯维公司发布了其 2025 年 10-K 表格报告，展示了强劲的财务表现，净收入为 611.6 亿美元，比去年增长了 8.6%。主要亮点包括免疫学领域的增长、新产品发布以及长期增长的战略举措。公司面临的挑战包括专利到期、监管压力和供应链风 | [Link](https://longbridge.com/zh-HK/news/276480798.md) | --- > **免責聲明**：本文內容僅供參考，不構成任何投資建議。